Sandra Horning, Jeff Rumens for Endpoints #JPM19
February 3, 2020 08:50 AM EST
R&D

Roche vet San­dra Horn­ing jumps on bio­phar­ma board no. 3 — what’s that worth?

John Carroll

Editor & Founder

San­dra Horn­ing is in high de­mand.

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Up­dat­ed: Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force as CEO de­parts

In sur­prise move, FDA's No. 2 Bum­pus to leave agency at end of 2024

Ex­clu­sive: In­sitro makes head­way on the hard­er road, dis­cov­er­ing new ALS drug tar­get

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

No­vo Nordisk part­ners with Broad In­sti­tute spin­out Pho­tys af­ter the star­tup's lay­offs

A service from the Financial Times